InMode Ltd.

Good morning and welcome to the in-mode second quarter 2023 earnings results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the call over to Miri Sagal of MSIR. Please go ahead.

Thank you, Operator, and to everyone for joining us today. Welcome to InMode Second Quarter 2023 Earnings Call. Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements, and the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please go to the investor relations section of the company's website. Changes in business, competitive, technological, regulatory, and other factors could cause actual results to differ materially from those expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them except as required by law. With that, I'd like to pass the call over to Moshe Mizrachi, Chairman and CEO. Moshe, please go ahead.

Thank you, Miri, and to everyone for joining us. With me today are Dr. Michael Kreindel, our Co-Founder and Chief Technology Officer, Yair Malka, our Chief Financial Officer, Shakila Kani, our President in North America, Dr. Spiro Tarduro, our Chief Medical Officer, and Raphael Liekermann, our VP of Finance. Following the prepared remarks, we will be available to answer your questions. We're happy to report a record quarter on all fronts. We announced record revenue of $136.1 million, an increase of 20% compared to the second quarter of 2022. Sales from our platforms reach over 1,600 units, and the numbers of disposables sold totaled over 270,000, the most in our company history. As part of our ongoing global expansion, during the second quarter, we established two new subsidiaries, one in Japan and one in Germany, establishing subsidiaries in countries where we believe we should be selling directly and not through distributor is our philosophy and strategy. Currently, InMod is one of the only companies in the space where its founder are still actively involved in the management and the ownership. And I believe that our strong involvement and commitment is part of InMod DNA. InMode innovation support our growth and lead to a solid brand recognition within highly competitive aesthetic industry. To further secure our competitive advantage, in the next 12 months, we intend to invest heavily on product development and to launch a new minimal invasive technology and platform, upgraded Morpheus 8 technology with new features, a new hand-free family of platforms for face and body, and a new multi-application applicator platforms with new technologies. In addition, we plan to secure additional indication cleared by the FDA. There are currently eight FDA studies in process. Within the next 12 months, InMod Portfolio of platforms and indication will be completely new and upgraded. And we will continue aggressively enhance and protect our IP and patent. Lastly, we are happy to report that just last month, it will become part of the Russell 2000 index. This index is most widely quoted measure of the overall performance of small cap and mid cap stock. I would like to turn the call to Shaquille, our president in North America.